MarketPulse

TACTI-004 trial

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Phase III Trial Halts Development

Immutep shares plummet 82.6% after independent committee halts Phase III trial for lead candidate eftilagimod alfa due to futility.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep's Failed Trial Triggers Stock Collapse as Rosen Law Firm Launches Securities Investigation

Immutep's failed Phase III trial triggered an 82.6% stock collapse, prompting a securities investigation by The Rosen Law Firm into potential shareholder claims.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial; Class Action Lawsuit Looms

Immutep's stock crashed after discontinuing Phase III TACTI-004 trial for eftilagimod alfa due to futility, prompting securities litigation against the biotech firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plunges 82.6% After Failed Phase III Trial, Sparking Class Action

Immutep's $IMMP stock crashed after trial discontinuation announcement. Rosen Law Firm investigates securities claims for investor losses.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.
IMMPinvestor lossessecurities class action